Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products.

 WHY? As alleged in a recently filed securities fraud class action complaint, Zoetis, Inc. (NYSE: ZTS), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that:: (i) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs;(ii) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market;and(iii) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. Plaintiff alleges that the truth behind defendants' misrepresentations was revealed over the course of four disclosures spanning from August 5, 2025 to May 7, 2026. In the final disclosure on May 7, 2026, the Company reported first quarter 2026 financial results that reflected significant deterioration across its core Companion Animal business and sharply reduced its full-year guidance.

WHAT CAN YOU DO NOW? If you purchased Zoetis, Inc. (NYSE: ZTS), shares prior to January 14, 2025, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.  Alternatively, if you purchased Zoetis, Inc. shares between January 14, 2025 and May 6, 2026, you can participate in the class action.